Non-Small Cell Lung Cancer (NSCLC) Clinical Trial
— CheckMate73LOfficial title:
A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)
| Verified date | January 2024 |
| Source | Bristol-Myers Squibb |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab vs CCRT followed by durvalumab in participants with untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC).
| Status | Active, not recruiting |
| Enrollment | 888 |
| Est. completion date | December 3, 2026 |
| Est. primary completion date | July 7, 2025 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Eastern Cooperative Oncology Group (ECOG) performance status =1 - Locally advanced stage IIIA, IIIB, or IIIC (T1-2 N2-3 M0, T3 N1-3 M0, or T4 N0-3 M0) pathologically-confirmed NSCLC, according to 8th TNM classification. Participants who are not planned for potential curative surgical resection are eligible. - Newly diagnosed and treatment-naïve, with no prior local or systemic anticancer therapy given as primary therapy for locally advanced disease Exclusion Criteria: - Any condition including medical, emotional, psychiatric, or logistical that, in the opinion of the Investigator would preclude the participant from adhering to the protocol or would increase the risk associated with study participation - Active infection requiring systemic therapy within 14 days prior to randomization - History of organ or tissue transplant that requires systemic use of immune suppressive agents - Prior thoracic radiotherapy Other protocol-defined inclusion/exclusion criteria apply |
| Country | Name | City | State |
|---|---|---|---|
| Argentina | Local Institution - 0043 | Buenos Aires | Distrito Federal |
| Argentina | Local Institution - 0042 | Caba | Distrito Federal |
| Argentina | Local Institution - 0044 | Caba | Buenos Aires |
| Argentina | Local Institution - 0045 | Río Cuarto | Cordoba |
| Australia | Local Institution - 0028 | Adelaide | South Australia |
| Australia | Local Institution - 0224 | Ballarat Central | Victoria |
| Australia | Local Institution - 0031 | Darlinghurst | New South Wales |
| Australia | Local Institution - 0134 | Gosford | New South Wales |
| Australia | Local Institution - 0029 | Greenslopes | Queensland |
| Australia | Local Institution - 0033 | Kingswood | New South Wales |
| Australia | Local Institution | Melbourne | Victoria |
| Australia | Local Institution - 0052 | Melbourne | Victoria |
| Australia | Local Institution - 0030 | Murdoch | Western Australia |
| Belgium | Local Institution - 0003 | Bruxelles | |
| Belgium | Local Institution - 0001 | Gent | |
| Belgium | Local Institution - 0004 | Liege | |
| Belgium | Local Institution - 0002 | Yvoir | |
| Brazil | Local Institution - 0036 | Barretos | SAO Paulo |
| Brazil | Local Institution - 0037 | Blumenau | Santa Catarina |
| Brazil | Local Institution - 0234 | Ijui | RIO Grande DO SUL |
| Brazil | Local Institution - 0038 | Ipatinga | Minas Gerais |
| Brazil | Local Institution - 0034 | Porto Alegre | RIO Grande DO SUL |
| Brazil | Local Institution - 0035 | Rio de Janeiro | |
| Canada | Local Institution - 0237 | Chicoutimi | Quebec |
| Canada | Local Institution - 0127 | Kingston | Ontario |
| Canada | Local Institution - 0078 | Oshawa | Ontario |
| Canada | Local Institution - 0126 | Quebec | |
| Canada | Local Institution - 0070 | Rimouski | Quebec |
| Canada | Local Institution - 0092 | Trois-Rivieres | Quebec |
| Chile | Local Institution - 0041 | Santiago | Metropolitana |
| Chile | Local Institution - 0040 | Vina del Mar | Valparaiso |
| China | Local Institution - 0146 | Beijing | BEI |
| China | Local Institution - 0170 | Changchun | Jilin |
| China | Local Institution - 0183 | Changchun | Jilin |
| China | Local Institution - 0154 | Changsha | Hunan |
| China | Local Institution - 0186 | Chengdu | Sichuan |
| China | Local Institution - 0189 | Chengdu | Sichuan |
| China | Local Institution - 0149 | Chongqing | Chongqing |
| China | Local Institution - 0179 | Fuzhou | Fujian |
| China | Local Institution - 0180 | Gongzhuling | Jilin |
| China | Local Institution - 0192 | Guiyang | Guizhou |
| China | Local Institution - 0140 | Hangzhou | Zhejiang |
| China | Local Institution - 0147 | Hankou | Hubei |
| China | Local Institution - 0138 | Jinan | Shandong |
| China | Local Institution - 0184 | Linhai | Zhejiang |
| China | Local Institution - 0178 | Nanchang | Jiangxi |
| China | Local Institution - 0139 | Nanjing | Jiangsu |
| China | Local Institution - 0145 | Shanghai | Shanghai |
| China | Local Institution - 0148 | Wuhan | Hubei |
| China | Local Institution - 0150 | Wuhan | Hubei |
| China | Local Institution - 0164 | Xiamen | Fujian |
| France | Local Institution - 0086 | Bordeaux | |
| France | Local Institution - 0087 | Dijon | |
| France | Local Institution - 0081 | Lyon | |
| France | Local Institution - 0082 | Montpellier | |
| France | Local Institution - 0084 | Nantes | |
| France | Local Institution - 0091 | Paris | |
| France | Local Institution - 0227 | Paris | |
| France | Local Institution - 0090 | Paris Cedex 14 | |
| France | Local Institution - 0083 | Paris Cedex 5 | |
| France | Local Institution - 0089 | Tours Cedex 09 | |
| Germany | Local Institution - 0060 | Berlin | |
| Germany | Local Institution - 0063 | Essen | |
| Germany | Local Institution - 0076 | Grosshansdorf | |
| Germany | Local Institution - 0101 | Hamm | |
| Germany | Local Institution - 0073 | Heidelberg | |
| Germany | Local Institution - 0061 | Immenhausen | |
| Germany | Local Institution - 0062 | Kempten | |
| Germany | Local Institution - 0075 | Loewenstein | |
| Germany | Local Institution - 0109 | Mainz | |
| Germany | Local Institution - 0072 | Stuttgart | |
| Greece | Local Institution - 0135 | Athens | |
| Greece | Local Institution - 0161 | Athens | |
| Greece | Local Institution - 0136 | Larissa | |
| Greece | Local Institution - 0162 | N.Kifissia | |
| Ireland | Local Institution - 0023 | Dublin | |
| Ireland | Local Institution - 0024 | Dublin 8 | Dublin |
| Italy | Local Institution - 0068 | Brescia | |
| Italy | Aou Policlinico V. Emanuele Di Catania | Catania | |
| Italy | Azienda Ospedaliero-Universitaria Mater Domini | Catanzaro | |
| Italy | Ospedale San Luca | Lucca | |
| Italy | Istituto Europeo di Oncologia IRCCS | Milano | |
| Italy | ASST di Monza - Azienda Ospedaliera San Gerardo | Monza | |
| Italy | Azienda Ospedaliera Di Perugia | Perugia | |
| Japan | Local Institution - 0199 | Bunkyo-ku | Tokyo |
| Japan | Local Institution - 0200 | Chuo-ku | Tokyo |
| Japan | Local Institution - 0212 | Fukuoka-shi | Fukuoka |
| Japan | Local Institution - 0198 | Hidaka-shi | Saitama |
| Japan | Local Institution - 0203 | Kanazawa-shi | Ishikawa |
| Japan | Local Institution - 0174 | Kitaadachi-gun | Saitama |
| Japan | Local Institution - 0206 | Kobe | Hyogo |
| Japan | Local Institution - 0211 | Kurume-shi | Fukuoka |
| Japan | Local Institution - 0204 | Nagoya | Aichi |
| Japan | Local Institution - 0202 | Niigata-shi | Niigata |
| Japan | Local Institution - 0205 | Osaka-shi | Osaka |
| Japan | Local Institution - 0210 | Osakasayama | Osaka |
| Japan | Local Institution - 0197 | Ota | Gunma |
| Japan | Local Institution - 0195 | Sapporo-shi | Hokkaido |
| Japan | Local Institution - 0196 | Sendai-shi | Miyagi |
| Japan | Local Institution - 0232 | Ube | Yamaguchi |
| Japan | Local Institution - 0175 | Wakayama-shi | Wakayama |
| Japan | Local Institution - 0217 | Yokohama | Kanagawa |
| Japan | Local Institution - 0201 | Yokohama-Shi | Kanagawa |
| Japan | Local Institution - 0216 | Yokohama-shi | Kanagawa |
| Korea, Republic of | Local Institution - 0167 | Cheongju-si, Chungcheonbuk-do, | |
| Korea, Republic of | Local Institution - 0152 | Seoul | |
| Korea, Republic of | Local Institution - 0168 | Seoul | |
| Mexico | Local Institution - 0015 | Culiacan | Sinaloa |
| Mexico | Local Institution - 0067 | Df | Distrito Federal |
| Mexico | Local Institution - 0080 | Guadalajara | Jalisco |
| Mexico | Local Institution - 0027 | La Paz | BAJA Californa SUR |
| Mexico | Local Institution - 0014 | Monterrey | Nuevo LEON |
| Netherlands | Local Institution - 0006 | Amsterdam | |
| Netherlands | Local Institution - 0025 | Arnhem | |
| Netherlands | Local Institution - 0240 | Leiden | |
| Netherlands | Local Institution - 0005 | Maastrict | |
| Netherlands | Local Institution - 0026 | Veldhoven | |
| Poland | Local Institution - 0107 | Bydgoszcz | |
| Poland | Local Institution - 0102 | Gdansk | |
| Poland | Local Institution - 0104 | Krakow | |
| Poland | Local Institution - 0235 | Tomaszow Mazowiecki | |
| Puerto Rico | Local Institution - 0120 | Hato Rey | |
| Puerto Rico | GCM Medical Group, PSC - Hato Rey Site | San Juan | |
| Romania | Local Institution - 0018 | Bucharest | |
| Romania | Local Institution - 0222 | Bucuresti | |
| Romania | Local Institution - 0019 | Cluj-Napoca | |
| Romania | Local Institution - 0020 | Constanta | |
| Romania | Local Institution - 0017 | Craiova | |
| Romania | Local Institution - 0021 | Floresti/ Cluj | |
| Russian Federation | Local Institution | Moscow | |
| Russian Federation | Local Institution | Moscow | |
| Russian Federation | Local Institution | Moscow | |
| Russian Federation | Local Institution | St. Petersburg | |
| Singapore | Local Institution - 0171 | Singapore | |
| Spain | Local Institution - 0106 | Barcelona | |
| Spain | Local Institution - 0099 | Hospitalet de Llobregat | |
| Spain | Local Institution - 0095 | Madrid | |
| Spain | Local Institution - 0096 | Madrid | |
| Spain | Local Institution - 0098 | Pamplona | |
| Spain | Local Institution - 0105 | Santiago de Compostela | |
| Spain | Local Institution - 0097 | Sevilla | |
| Spain | Local Institution - 0100 | Zaragoza | |
| Sweden | Local Institution - 0065 | Goteborg | Vastra Gotalands Lan |
| Sweden | Local Institution - 0064 | Stockholm | |
| Switzerland | Local Institution - 0057 | Basel | |
| Switzerland | Local Institution - 0058 | Lausanne | |
| Switzerland | Local Institution - 0059 | St.Gallen | |
| Switzerland | Local Institution - 0056 | Zuerich | |
| Taiwan | Local Institution - 0208 | KaohsiungCity | |
| Taiwan | Local Institution - 0214 | New Taipei City | |
| Taiwan | Local Institution - 0209 | Tainan | |
| Taiwan | Local Institution - 0143 | Taipei | |
| Taiwan | Local Institution - 0213 | Taipei | |
| Taiwan | Local Institution - 0133 | Taipei City | |
| United Kingdom | Local Institution - 0054 | Aberdeen | |
| United Kingdom | Local Institution - 0007 | Bebington | |
| United Kingdom | Local Institution - 0009 | Hull | |
| United Kingdom | Local Institution - 0010 | Poole | Dorset |
| United Kingdom | Local Institution - 0012 | Swansea | Glamorgan |
| United States | Local Institution - 0125 | Atlanta | Georgia |
| United States | Local Institution - 0165 | Augusta | Georgia |
| United States | Local Institution - 0191 | Austin | Texas |
| United States | Local Institution - 0108 | Bethesda | Maryland |
| United States | Local Institution - 0079 | Bryan | Texas |
| United States | Local Institution - 0071 | Burlington | Vermont |
| United States | Local Institution - 0077 | Charleston | South Carolina |
| United States | Local Institution - 0053 | Cincinnati | Ohio |
| United States | Local Institution - 0131 | Cincinnati | Ohio |
| United States | Local Institution - 0188 | Cincinnati | Ohio |
| United States | Local Institution - 0047 | Cleveland | Ohio |
| United States | Local Institution - 0112 | Cleveland | Ohio |
| United States | Local Institution - 0124 | Cleveland | Ohio |
| United States | Local Institution - 0130 | Dallas | Texas |
| United States | Local Institution - 0218 | Edgewood | Kentucky |
| United States | Local Institution - 0233 | Jacksonville | Florida |
| United States | Local Institution - 0119 | La Jolla | California |
| United States | Local Institution - 0129 | Lone Tree | Colorado |
| United States | Local Institution - 0219 | Orlando | Florida |
| United States | Local Institution - 0039 | Pensacola | Florida |
| United States | Local Institution - 0166 | San Francisco | California |
| United States | Local Institution - 0207 | San Francisco | California |
| United States | Local Institution - 0116 | Traverse City | Michigan |
| United States | Local Institution - 0123 | Youngstown | Ohio |
| Lead Sponsor | Collaborator |
|---|---|
| Bristol-Myers Squibb |
United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Greece, Ireland, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russian Federation, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Progression-free survival (PFS) by RECIST 1.1 per Blinded Independent Central Review (BICR) for Arm A vs Arm C | Up to 7 years | ||
| Secondary | Overall Survival (OS) for Arm A vs Arm C | Up to 7 years | ||
| Secondary | PFS by RECIST 1.1 per BICR for Arm B vs Arm C | Up to 7 years | ||
| Secondary | OS for Arm B vs Arm C | Up to 7 years | ||
| Secondary | PFS by RECIST 1.1 per BICR for Arm A vs Arm B | Up to 7 years | ||
| Secondary | OS for Arm A vs Arm B | Up to 7 years | ||
| Secondary | Objective Response Rate (ORR) by RECIST 1.1 per BICR | Up to 7 years | ||
| Secondary | Duration of Response (DoR) by RECIST 1.1 per BICR | Up to 7 years | ||
| Secondary | Time to Response (TTR) by RECIST 1.1 per BICR | Up to 7 years | ||
| Secondary | PFS by RECIST 1.1 per Investigator assessment | Up to 7 years | ||
| Secondary | ORR by RECIST 1.1 per Investigator assessment | Up to 7 years | ||
| Secondary | DoR by RECIST 1.1 per Investigator assessment | Up to 7 years | ||
| Secondary | TTR by RECIST 1.1 per Investigator assessment | Up to 7 years | ||
| Secondary | Time to Death or Distant Metastases (TTDM) by RECIST 1.1 per Investigator assessment | Up to 7 years | ||
| Secondary | Incidence of Adverse Events (AEs) | Up to 7 years | ||
| Secondary | Incidence of Serious Adverse Events (SAEs) | Up to 7 years | ||
| Secondary | Incidence of select AEs | Up to 7 years | ||
| Secondary | Proportion of participants without symptom deterioration based on NSCLC-SAQ | Non-Small Cell Lung Cancer-Symptom Assessment Questionnaire (NSCLC-SAQ) | Up to 7 years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06040541 -
Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT03667820 -
Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
|
Phase 2 | |
| Completed |
NCT02025114 -
Selumetinib in Combination With Gefitinib in NSCLC Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01994057 -
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
|
||
| Completed |
NCT01438307 -
Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT01193959 -
Pemetrexed in Advanced Non-small Cell Lung Cancer
|
||
| Recruiting |
NCT01028729 -
A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)
|
Phase 4 | |
| Completed |
NCT00770588 -
Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)
|
Phase 4 | |
| Recruiting |
NCT05462717 -
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
|
Phase 1 | |
| Completed |
NCT01951157 -
A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
|
Phase 2 | |
| Recruiting |
NCT01964157 -
An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement
|
Phase 2 | |
| Recruiting |
NCT05585320 -
A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03260491 -
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT05207423 -
A Chart Review Study of Adults With Advanced NSCLC
|
||
| Terminated |
NCT02608528 -
Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy
|
||
| Completed |
NCT01463423 -
Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)
|
N/A | |
| Recruiting |
NCT02927340 -
A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions
|
Phase 2 | |
| Recruiting |
NCT02521051 -
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT02403193 -
Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
|
Phase 1 |